. 2023 Jun 2;13:8998. doi: 10.1038/s41598-023-35764-7

Table 4.

Plasma lipids, HDL composition, and HDL-mediated cholesterol efflux according to clinical stages of BC.

	I	II	III	IV	P
n	57	57	31	16
Age (years)	60 (49–64)	53 (46–61)	56 (51–61)	55 (48–66)	0.287
BMI (kg/m²)	27 (24–31)	28 (25–31)	27 (25–31)	25 (23–30)	0.291
Ki67	20 (10–30)	20 (10–30)	30 (20–70)	35 (30–72)	< 0.001 I–III < 0.001 I–IV < 0.001 II–III 0.015 II–IV 0.005 III–IV 0.416 I–II 0.122
TC (mg/dL)	187 (162–218)	179 (155–203)	189 (167–208)	183 (154–241)	0.600
TG (mg/dL)	94 (64–117)	92 (73–122)	92 (73–115)	84 (60–111)	0.760
apoB (mg/dL)	105 (81–138)	107 (87–137)	109 (84–141)	105 (84–150)	0.972
HDLc (mg/dL)	42 (33–51)	42 (33–50)	46 (39–55)	41 (33–45)	0.376
LDLc (mg/dL)	121 (98–146)	109 (92–137)	118 (97–139)	117 (98–172)	0.476
VLDLc (mg/dL)	21 (13–28)	17 (13–22)	16 (13–21)	20 (18–27)	0.760
non-HDLc (mg/dL)	140 (118–169)	132 (105–159)	139 (116–163)	132 (108–196)	0.640
TC/apoB	1.8 (1.4–2.1)	1.7 (1.4–2.0)	1.7 (1.4–2.0)	1.6 (1.2–2.0)	0.685
TG/HDLc	1.9 (1.5–3.2)	2.3 (1.4–3.3)	2.1 (1.0–3.3)	2.4 (1.6–2.7)	0.875
HDL-TC (mg/dL)	44 (30–51)	38 (28–49)	45 (26–67)	38 (31–51)	0.336
HDL-TG (mg/dL)	15 (12–44)	15 (11–39)	38 (14–92)	18 (10–56)	0.032 I–IV 0.831 II–IV 0.809 III–IV 0.035 I–II 0.968 –III 0.009 II–III 0.009
HDL-PL (mg/dL)	90 (75–119)	89 (76–114)	117 (87–124)	87 (79–113)	0.116
HDL-apoA-I (mg/dL)	116 (83–144)	104 (78–135)	114 (85–141)	109 (94–149)	0.733
24HC (ng/mL)	31 (19–48)	35 (26–75)	28 (25–50)	56 (34–128)	0.276
25HC (ng/mL)	6.5 (5.1–8.5)	7.1 (5.3–8.7)	9.7 (6.6–10.6)	6.0 (4.3–8.9)	0.247
27HC (ng/mL)	8.8 (4.6–15.1)	9.7 (4.6–14.4)	5.0 (3.9–9.1)	5.7 (3.4–10.1)	0.267
¹⁴C-cholesterol efflux (%)	14 (10–20)	13 (10–18)	9 (7–15)	9 (7–12)	0.011 III–IV 0.424 II–IV 0.014 I–IV 0.004 II–III 0.088 I–III 0.033 I–II 0.578

III

Age (years)

(49–64)

(46–61)

(51–61)

(48–66)

0.287

BMI (kg/m²)

(24–31)

(25–31)

(23–30)

0.291

Ki67

(10–30)

(20–70)

(30–72)

< 0.001

I–III < 0.001

I–IV < 0.001

II–III 0.015

II–IV 0.005

III–IV 0.416

I–II 0.122

TC (mg/dL)

187

(162–218)

179

(155–203)

189

(167–208)

183

(154–241)

0.600

TG (mg/dL)

(64–117)

(73–122)

(73–115)

(60–111)

0.760

apoB (mg/dL)

105

(81–138)

107

(87–137)

109

(84–141)

105

(84–150)

0.972

HDLc (mg/dL)

(33–51)

(33–50)

(39–55)

(33–45)

0.376

LDLc (mg/dL)

121

(98–146)

109

(92–137)

118

(97–139)

117

(98–172)

0.476

VLDLc (mg/dL)

(13–28)

(13–22)

(13–21)

(18–27)

0.760

non-HDLc (mg/dL)

140

(118–169)

132

(105–159)

139

(116–163)

132

(108–196)

0.640

TC/apoB

1.8

(1.4–2.1)

1.7

(1.4–2.0)

1.7

(1.4–2.0)

1.6

(1.2–2.0)

0.685

TG/HDLc

1.9

(1.5–3.2)

2.3

(1.4–3.3)

2.1

(1.0–3.3)

2.4

(1.6–2.7)

0.875

HDL-TC (mg/dL)

(30–51)

(28–49)

(26–67)

(31–51)

0.336

HDL-TG (mg/dL)

(12–44)

(11–39)

(14–92)

(10–56)

0.032

I–IV 0.831

II–IV 0.809

III–IV 0.035

I–II 0.968

–III 0.009

II–III 0.009

HDL-PL (mg/dL)

(75–119)

(76–114)

117

(87–124)

(79–113)

0.116

HDL-apoA-I (mg/dL)

116

(83–144)

104

(78–135)

114

(85–141)

109

(94–149)

0.733

24HC (ng/mL)

(19–48)

(26–75)

(25–50)

(34–128)

0.276

25HC (ng/mL)

6.5

(5.1–8.5)

7.1

(5.3–8.7)

9.7

(6.6–10.6)

6.0

(4.3–8.9)

0.247

27HC (ng/mL)

8.8

(4.6–15.1)

9.7

(4.6–14.4)

5.0

(3.9–9.1)

5.7

(3.4–10.1)

0.267

¹⁴C-cholesterol efflux (%)

(10–20)

(10–18)

(7–15)

(7–12)

0.011

III–IV 0.424

II–IV 0.014

I–IV 0.004

II–III 0.088

I–III 0.033

I–II 0.578

Plasma lipids were determined by enzymatic colorimetric methods and apoB by immunoturbidimetry. HDLc was determined after precipitation of lipoproteins containing apoB; non-HDLc was calculated as TC-HDLc. Oxysterols were quantified in isolated HDL by gas chromatography-mass spectrometry (GC–MS). The cholesterol efflux was determined in BMDM overloaded with ¹⁴C-cholesterol and acetylated LDL, utilizing 50 µg/mL of HDL as a cholesterol acceptor.

CTR, control women; BC, breast cancer; BMI, body mass index; TC, total cholesterol; TG, triglycerides; apoB, apolipoprotein B; HDLc, high-density lipoprotein cholesterol; LDLc, low density lipoprotein cholesterol; VLDLc, very low density lipoprotein cholesterol; PL, phospholipids; apoA-I, apolipoprotein A-I; 24HC, 24-hydroxycholesterol (CTR, n = 82; BC, n = 82); 25HC, 25-hydroxycholesterol (CTR, n = 82; BC, n = 82); 27HC, 27-hydroxycholesterol (CTR, n = 81; BC, n = 80). Comparisons were made using the Kruskall-Wallis test with a significance of 0.05. Data shown in median and interquartile ranges (25–75%).